Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Steve Cohen’s Point72 Asset Management filed an amended 13D.
You can check out Point72 Asset Management’s latest holdings and filings here.
Please follow Point72 Asset Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Point72 Asset Management or update its stock holdings.
Follow Steven A. Cohen's Point72 Asset Management
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Point7 | 0 | 3,466,000 | 0 | 3,466,000 | 3,466,000 | 7.3% |
Point7 | 0 | 3,466,000 | 0 | 3,466,000 | 3,466,000 | 7.3% |
Cubist Systematic Strategies | 0 | 963 | 0 | 963 | 963 | Less than 0.1% |
Point7 | 0 | 334 | 0 | 334 | 334 | Less than 0.1% |
Steven A. Cohen | 0 | 3,467,297 | 0 | 3,467,297 | 3,467,297 | 7.3% |
Follow Steven A. Cohen's Point72 Asset Management
Page 1 of 11 – SEC Filing
(Amendment No. )*
KARYOPHARM THERAPEUTICS INC.
Common Stock, Par Value $0.0001 Per Share
☐ | Rule 13d-1(b) | |
☒ | Rule 13d-1(c) | |
☐ | Rule 13d-1(d) |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 2 of 11 – SEC Filing
CUSIP No. 48576U106 | 13G | Page 2 of 11 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Point72 Asset Management, L.P. | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 3,466,000 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 3,466,000 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,466,000 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.3% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* PN |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 3 of 11 – SEC Filing
CUSIP No. 48576U106 | 13G | Page 3 of 11 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Point72 Capital Advisors, Inc. | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 3,466,000 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 3,466,000 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,466,000 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.3% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* CO |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 4 of 11 – SEC Filing
CUSIP No. 48576U106 | 13G | Page 4 of 11 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Cubist Systematic Strategies, LLC | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 963 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 963 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 963 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) Less than 0.1% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* OO |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 5 of 11 – SEC Filing
CUSIP No. 48576U106 | 13G | Page 5 of 11 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Point72 Asia (Hong Kong) Limited | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION Hong Kong | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 334 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 334 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 334 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) Less than 0.1% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* OO |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 6 of 11 – SEC Filing
CUSIP No. 48576U106 | 13G | Page 6 of 11 Pages |
1 | NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Steven A. Cohen | ||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐ (b) ☒ | ||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 0 | |
6 | SHARED VOTING POWER 3,467,297 (see Item 4) | ||
7 | SOLE DISPOSITIVE POWER 0 | ||
8 | SHARED DISPOSITIVE POWER 3,467,297 (see Item 4) | ||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,467,297 (see Item 4) | ||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ | ||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.3% (see Item 4) | ||
12 | TYPE OF REPORTING PERSON* IN |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 7 of 11 – SEC Filing
Item 1(a) | Name of Issuer: |
Karyopharm Therapeutics Inc. | |
Item 1(b) | Address of Issuer’s Principal Executive Offices: |
85 Wells Avenue, 2nd Floor, Newton, MA 02459 | |
Item 2(a) | Name of Person Filing: |
This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.0001 per share (“Shares”), of the Issuer held by certain investment funds it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by certain investment funds managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to Shares held by certain investment funds it manages; (iv) Point72 Asia (Hong Kong) Limited (“Point72 Asia (Hong Kong)”) with respect to Shares held by certain investment funds it manages; and (v) Steven A. Cohen with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Point72 Asia (Hong Kong). | |
Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72 Asia (Hong Kong), and Steven A. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act. | |
Item 2(b) | Address or Principal Business Office: |
The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; (ii) Cubist Systematic Strategies is 330 Madison Avenue, New York, NY 10173; and (iii) Point72 Asia (Hong Kong) is 17th Floor, York House, The Landmark, 15 Queen’s Road Central, Hong Kong. | |
Item 2(c) | Citizenship: |
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Point72 Asia (Hong Kong) is a Hong Kong limited liability company. Mr. Cohen is a United States citizen. | |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 8 of 11 – SEC Filing
Item 2(d) | Title of Class of Securities: |
Common Stock, par value $0.0001 per share | |
Item 2(e) | CUSIP Number: |
48576U106 | |
Item 3 | Not Applicable |
Item 4 | Ownership: |
The percentages used herein are calculated based upon the Shares issued and outstanding as of October 30, 2017, as reported on the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer for the quarterly period ended September 30, 2017. | |
As of the close of business on November 3, 2017: | |
1. Point72 Asset Management, L.P. | |
(a) Amount beneficially owned: 3,466,000 | |
(b) Percent of class: 7.3% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 3,466,000 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 3,466,000 | |
2. Point72 Capital Advisors, Inc. | |
(a) Amount beneficially owned: 3,466,000 | |
(b) Percent of class: 7.3% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 3,466,000 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 3,466,000 | |
3. Cubist Systematic Strategies, LLC | |
(a) Amount beneficially owned: 963 | |
(b) Percent of class: less than 0.1% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 963 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 963 | |
4. Point72 Asia (Hong Kong) Limited | |
(a) Amount beneficially owned: 334 | |
(b) Percent of class: less than 0.1% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 334 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 334 | |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 9 of 11 – SEC Filing
5. Steven A. Cohen | |
(a) Amount beneficially owned: 3,467,297 | |
(b) Percent of class: 7.3% | |
(c)(i) Sole power to vote or direct the vote: -0- | |
(ii) Shared power to vote or direct the vote: 3,467,297 | |
(iii) Sole power to dispose or direct the disposition: -0- | |
(iv) Shared power to dispose or direct the disposition: 3,467,297 | |
Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72 Asia (Hong Kong), and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by certain investment funds it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by certain investment funds it manages. Pursuant to an investment management agreement, Point72 Asia (Hong Kong) maintains investment and voting power with respect to the securities held by certain investment funds it manages. Mr. Cohen controls each of Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Point72 Asia (Hong Kong). By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen may be deemed to beneficially own 3,466,000 Shares (constituting approximately 7.3% of the Shares outstanding); (ii) Cubist Systematic Strategies and Mr. Cohen may be deemed to beneficially own 963 Shares (constituting less than 0.1% of the Shares outstanding); and (iii) Point72 Asia (Hong Kong) and Mr. Cohen may be deemed to beneficially own 334 Shares (constituting less than 0.1% of the Shares outstanding). Each of Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72 Asia (Hong Kong), and Mr. Cohen disclaims beneficial ownership of any of the securities covered by this statement. | |
Item 5 | Ownership of Five Percent or Less of a Class: |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐ | |
Item 6 | Ownership of More than Five Percent on Behalf of Another Person: |
Not Applicable | |
Item 7 | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: |
Not Applicable | |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 10 of 11 – SEC Filing
Item 8 | Identification and Classification of Members of the Group: |
Not Applicable | |
Item 9 | Notice of Dissolution of Group: |
Not Applicable | |
Item 10 | Certification: |
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Page 11 of 11 – SEC Filing
CUBIST SYSTEMATIC STRATEGIES, LLC
POINT72 ASIA (HONG KONG) LIMITED
STEVEN A. COHEN